Ocular Therapeutix, Inc. (OCUL)

5.0000 -0.0750 (-1.48%) At close: 04:00PM EDT

Ocular Therapeutix, Inc.

15 Crosby Drive
Bedford, MA 01730
United States
781 357 4000
https://www.ocutx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 267

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Donald Notman Jr.	Chief Financial Officer	630.87k	N/A	N/A
Dr. Jeffrey S. Heier M.D.	Chief Scientific Officer	84.88k	N/A	1961
Dr. Rabia Gurses Ozden M.D.	Chief Medical Officer	621.39k	N/A	1969
Dr. Pravin U. Dugel M.D.	Executive Chairman, President & CEO	N/A	N/A	1964
Dr. Karen-Leigh Edwards M.B.A., Ph.D.	Chief Operations Officer	N/A	N/A	N/A
Dr. Peter K. Jarrett Ph.D.	Chief Technology Officer	N/A	N/A	1957
Mr. Philip C. Strassburger Esq.	General Counsel	282.61k	N/A	1960
Mr. William H. Ransone II	Vice President of Global Sales & Marketing	N/A	N/A	N/A
Ms. Tracy Smith	Vice President of Human Resources	N/A	N/A	N/A
Mr. Steve Meyers	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Corporate governance

Ocular Therapeutix, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.